Interpretation of results of the cost-effectiveness analysis reported by Pellissier et al. on October 2007

Vaccine. 2008 Sep 26;26(41):5244; author reply 5245. doi: 10.1016/j.vaccine.2008.06.063. Epub 2008 Jul 9.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Cost-Benefit Analysis*
  • Herpes Zoster / prevention & control*
  • Herpes Zoster Vaccine / economics*
  • Humans
  • Mass Vaccination / economics
  • Middle Aged

Substances

  • Herpes Zoster Vaccine